You just read:

PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy

News provided by

PTC Therapeutics, Inc.

Jun 06, 2017, 08:00 ET